Alberto Hernando‐Calvo

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco et al. · Nature · 2024 · 93 citations · Full text

Life Sciences, Immunology, Oncology +17

Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.

Glenn J. Hanna, John M. Kaczmar, Dan P. Zandberg et al. · Journal of Clinical Oncology · 2023 · 30 citations

Medicine, Oncology, Pharmacology +17

Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients

Alberto Hernando‐Calvo, Alejandro García‐Álvarez, Guillermo Villacampa et al. · Clinical & Translational Oncology · 2020 · 22 citations

Medicine, Immunology, Oncology +16

Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients

Alberto Hernando‐Calvo, Oriol Mirallas, David Marmolejo et al. · Oral Oncology · 2023 · 20 citations · Full text

Medicine, Immunology, Oncology +17

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

Alberto Hernando‐Calvo, María Vila-Casadesús, Yacine Barèche et al. · Med · 2023 · 17 citations · Full text

Medicine, Immunology, Oncology +17